CITIGROUP INC (C)
SEC filings, financial facts, source resources, and Goglides workspace context for CITIGROUP INC.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
4Results3Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
C: Citi's global scale only works if simplification lifts returns
Citigroup is a globally important bank with FY2025 revenue of $85.2 billion, Q1 2026 revenue of $24.6 billion and $1.45 trillion of deposits, but the thesis depends on deposit stability, credit, capital and simplification execution.
OpenAGBK: the profitable Brazil bank whose growth depends on one regulatory gate
AGI Inc came public with Banco Agibank scale, 7.1 million active clients, a R$35.5 billion credit portfolio and post-IPO capital strength, but the thesis turns on INSS access, credit quality, funding spreads and founder-controlled governance.
OpenAFYA: Brazil's medical-school seat machine is profitable, but regulation is the moat and the risk
Afya is a profitable Brazilian medical education platform built around scarce regulated medical-school seats. The thesis rests on seat maturation, tuition durability, cash conversion and whether the newer physician ecosystem can grow without undermining margin
Open